Olema Pharmaceuticals, Inc.

OLMA · United States

Share price · OLMA

$7.06-3.59 (-33.71%) 3M

close as of 2026-11-18 · 24h delayed · vol 1.2M (0.8x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when OLMA's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 11 Nov 2026+10.6%
  2. 6 Nov 2026+8.4%
  3. 23 Oct 2026-8.7%
  4. 19 Oct 2026+8.1%
  5. 11 Aug 2026-12.6%
  6. 16 Jun 2026-7.0%
  7. 2 Jun 2026-15.9%
  8. 16 Mar 2026+12.8%
  9. 9 Mar 2026-25.8%
  10. 18 Nov 2025+136.4%

Share of unusual movement by asset

For each asset, the share of OLMA's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
OP-3136
events and moves
5shown from 8 days
Palazestrant
events and moves
3shown from 8 days
Assets with fewer than 8 event days, together—3%
Other company news (earnings, financing, releases naming no asset)—68%
Sessions with no dated event—29%

Assets

(2 total)
2Total Assets
0Approved
1Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 3
Estrogen receptorSmall molecule
Breast Cancer
HR+/HER2- Metastatic Breast Cancer
Phase 1
KAT6A / KAT6BSmall molecule
Non-Small Cell Lung CancerBreast Cancer
HR+/HER2- Metastatic Breast Cancer

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
December 2028 (1)
PalazestrantPhase 3Breast Cancer, Locally Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer, HER2 Negative Breast Carcinoma
Est. primary completion 2028-12 · NCT07085767 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$68M$48M+ $366M short-term inv.$74M-$47M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$58M$49M+ $412M short-term inv.$63M-$46M operating cash flowreport ↗
2026-Q1—$49M$53M+ $453M short-term inv.$53M-$46M operating cash flowreport ↗
2025-Q3—$40M$35M+ $294M short-term inv.$42M-$35M operating cash flowreport ↗
2025-Q2—$44M$52M+ $309M short-term inv.$44M-$30M operating cash flowreport ↗
2025-Q1—$31M$51M+ $342M short-term inv.$30M-$44M operating cash flowreport ↗
2024-Q3—$33M$36M+ $179M short-term inv.$35M-$27M operating cash flowreport ↗
2024-Q2—$29M$17M+ $222M short-term inv.$30M-$28M operating cash flowreport ↗
2024-Q1—$30M$34M+ $215M short-term inv.$31M-$24M operating cash flowreport ↗
2023-Q3—$19M$117M+ $159M short-term inv.$22M-$23M operating cash flowreport ↗
2023-Q2—$18M$35M+ $132M short-term inv.$20M-$22M operating cash flowreport ↗
2023-Q1—$23M$41M+ $145M short-term inv.$28M-$20M operating cash flowreport ↗
2022-Q3—$18M$27M+ $196M short-term inv.$23M-$18M operating cash flowreport ↗
2022-Q2—$27M$25M+ $216M short-term inv.$33M-$26M operating cash flowreport ↗
2022-Q1—$16M$22M+ $246M short-term inv.$23M-$18M operating cash flowreport ↗
2021-Q3—$13M$26M+ $280M short-term inv.$18M-$12M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$158M$48M+ $457M short-term inv.$41M-$147M operating cash flowreport ↗

For full-year 2025, Olema Pharmaceuticals did not disclose revenue, while R&D spend was $157.7M, up 26.6% YoY from $124.52M. The company ended the year with cash and equivalents of $48.3M and cash, equivalents, and marketable securities of $505.4M, and reported a net loss of $162.45M.

The company expects top-line data from the pivotal Phase 3 OPERA-01 trial of palazestrant in the fall of 2026, with initial clinical data from the OP-3136 Phase 1 study expected in Q2 2026 and a potential first commercial launch in late 2027. During the year, enrollment advanced in the OPERA-02 Phase 3 trial, a Phase 1b/2 study of palazestrant with atirmociclib was initiated, and a follow-on public offering generated approximately $218.5M in gross proceeds to strengthen the balance sheet.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$125M$139M+ $295M short-term inv.$32M-$104M operating cash flowreport ↗
2023-FY—$86M$69M+ $193M short-term inv.$24M-$84M operating cash flowreport ↗
2022-FY—$82M$24M+ $181M short-term inv.$26M-$82M operating cash flowreport ↗
2021-FY—$51M$14M+ $273M short-term inv.$18M-$51M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 25 sales ($24.7M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-09-01O'Byrne Jason · CHIEF FINANCIAL OFFICERAward / grant (derivative)650,000——Form 4
2026-07-24Harmon Cyrus · directorOpen-market sale12,500$11.71$146KForm 4
2026-07-23Harmon Cyrus · directorOpen-market sale12,500$11.58$145KForm 4
2026-06-18Graham G. Walmsley · directorAward / grant (derivative)29,500——Form 4
2026-06-18RAPPAPORT ANDREW · directorAward / grant (derivative)29,500——Form 4
2026-06-18Raman Prakash · directorAward / grant (derivative)29,500——Form 4
2026-06-18Horning Sandra · directorAward / grant (derivative)29,500——Form 4
2026-06-18Larson Yi · directorAward / grant (derivative)29,500——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 195 reporting institutions held 101.5M shares ($1.5B, 115.8% of shares outstanding).

#InstitutionSharesValue
1FMR LLC10,386,845$154.9M
2Paradigm Biocapital Advisors LP8,020,576$119.6M
3Bain Capital Life Sciences Investors, LLC7,473,238$111.4M
4JANUS HENDERSON GROUP PLC7,108,488$106.0M
5BlackRock, Inc.5,652,135$84.3M
6BVF INC/IL5,295,893$79.0M
7Siren, L.L.C.4,756,949$70.9M
8STATE STREET CORP3,937,831$58.7M
9Cormorant Asset Management, LP3,900,000$58.1M
10Logos Global Management LP3,208,875$47.8M
11VANGUARD CAPITAL MANAGEMENT LLC3,083,517$46.0M
12RA CAPITAL MANAGEMENT, L.P.2,600,000$38.8M
13JENNISON ASSOCIATES LLC1,822,123$27.2M
14Polar Capital Holdings Plc1,602,970$23.9M
15GEODE CAPITAL MANAGEMENT, LLC1,544,417$23.0M